Petach-Tikva, Israel

Shimon Nahum

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Azura Ophthalmics Ltd.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shimon Nahum: Innovator in Ophthalmic Treatments

Introduction

Shimon Nahum is a notable inventor based in Petach-Tikva, Israel. He has made significant contributions to the field of ophthalmology, particularly in the treatment of meibomian gland dysfunction. His innovative approach has led to the development of a unique composition that addresses this common eye condition.

Latest Patents

Shimon Nahum holds a patent for the manufacturing of selenium disulfide compositions. This patent describes methods for creating stable anhydrous compositions of selenium disulfide that are free from agglomerates and degradation products. The methods utilize the rheological properties of petrolatum, enhanced by a high shear mixing feature, to produce effective treatments for meibomian gland dysfunction.

Career Highlights

Throughout his career, Nahum has focused on developing solutions that improve eye health. His work has been instrumental in advancing the understanding and treatment of conditions affecting the meibomian glands. With a patent portfolio that includes one significant patent, he continues to contribute to the field of ophthalmic research.

Collaborations

Shimon Nahum collaborates with talented professionals in his field, including Yair Alster and Hila Epstein-Barash. These partnerships enhance the innovation process and contribute to the development of effective treatments.

Conclusion

Shimon Nahum's work in the field of ophthalmology exemplifies the impact of innovative thinking on healthcare. His patented methods for manufacturing selenium disulfide compositions represent a significant advancement in the treatment of meibomian gland dysfunction.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…